218 related articles for article (PubMed ID: 25160519)
1. PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward.
Pal SK; Singh P; Vogelzang NJ
Clin Genitourin Cancer; 2015 Aug; 13(4):257-260. PubMed ID: 25160519
[No Abstract] [Full Text] [Related]
2. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of PD-1 and its ligands in renal cell carcinoma.
Erlmeier F; Weichert W; Schrader AJ; Autenrieth M; Hartmann A; Steffens S; Ivanyi P
Med Oncol; 2017 Jun; 34(6):99. PubMed ID: 28432616
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
6. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.
Martini DJ; Hamieh L; McKay RR; Harshman LC; Brandao R; Norton CK; Steinharter JA; Krajewski KM; Gao X; Schutz FA; McGregor B; Bossé D; Lalani AA; De Velasco G; Michaelson MD; McDermott DF; Choueiri TK
Cancer Immunol Res; 2018 Apr; 6(4):402-408. PubMed ID: 29437040
[TBL] [Abstract][Full Text] [Related]
7. Novel challenges associated with novel agents: the evolving scenario in renal cell carcinoma.
Di Lorenzo G; Buonerba C
Future Oncol; 2016 Feb; 12(3):277-9. PubMed ID: 26768297
[No Abstract] [Full Text] [Related]
8. Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens.
Basu A; Yearley JH; Annamalai L; Pryzbycin C; Rini B
Am J Clin Pathol; 2019 Jan; 151(2):217-225. PubMed ID: 30346474
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
11. Kidney cancer: PDL1 as a biomarker in high-risk RCC.
Kelsey R
Nat Rev Urol; 2018 Apr; 15(4):202. PubMed ID: 29434371
[No Abstract] [Full Text] [Related]
12. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
Harshman LC; Drake CG; Choueiri TK
Cancer Immunol Res; 2014 Dec; 2(12):1132-41. PubMed ID: 25480555
[TBL] [Abstract][Full Text] [Related]
13. Impact of PD-L1 Protein Expression on Renal Cell Carcinoma Histo-differentiation.
Tziakou P; Theodoropoulos G; Tsiambas E; Zizi-Sermpetzoglou A; Peschos D; Mastronikoli S; Thomopoulou G; Thymara E; Kavantzas N; Lazaris AC
Anticancer Res; 2021 Aug; 41(8):3809-3813. PubMed ID: 34281840
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers to predict prognosis and response to checkpoint inhibitors.
Yuasa T; Masuda H; Yamamoto S; Numao N; Yonese J
Int J Clin Oncol; 2017 Aug; 22(4):629-634. PubMed ID: 28382562
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
[TBL] [Abstract][Full Text] [Related]
16. Emerging Immunotargets in Metastatic Renal Cell Carcinoma.
Kucharczyk J; Matrana MR; Santoni M; Massari F; Scarpelli M; Cheng L; Lopez-Beltran A; Cascinu S; Montironi R; Holger M
Curr Drug Targets; 2016; 17(7):771-6. PubMed ID: 26648075
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
Rahman W; Conley A; Silver KD
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32616532
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1/PD-L1 therapy for renal cell carcinoma: challenges in the development of predictive biomarkers.
Kato R; Obara W
Expert Rev Anticancer Ther; 2022 Jul; 22(7):667-669. PubMed ID: 35670624
[No Abstract] [Full Text] [Related]
19. Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma.
Brugarolas J
J Natl Compr Canc Netw; 2016 Jul; 14(7):925-7. PubMed ID: 27407131
[No Abstract] [Full Text] [Related]
20. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
